Invesco Ltd. Has $1.15 Million Holdings in Kymera Therapeutics, Inc. $KYMR

Invesco Ltd. raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 36.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,075 shares of the company’s stock after buying an additional 11,343 shares during the quarter. Invesco Ltd. owned about 0.06% of Kymera Therapeutics worth $1,152,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after buying an additional 344,080 shares during the last quarter. Driehaus Capital Management LLC raised its stake in shares of Kymera Therapeutics by 4.6% in the fourth quarter. Driehaus Capital Management LLC now owns 1,390,372 shares of the company’s stock valued at $55,935,000 after purchasing an additional 61,669 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new position in shares of Kymera Therapeutics in the fourth quarter valued at $23,856,000. Woodline Partners LP raised its stake in shares of Kymera Therapeutics by 2.3% in the fourth quarter. Woodline Partners LP now owns 537,428 shares of the company’s stock valued at $21,621,000 after purchasing an additional 12,334 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Kymera Therapeutics by 14.0% in the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company’s stock valued at $17,614,000 after purchasing an additional 53,658 shares in the last quarter.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $41.20 on Tuesday. The stock has a fifty day moving average price of $43.65 and a two-hundred day moving average price of $36.84. The firm has a market capitalization of $2.95 billion, a P/E ratio of -11.87 and a beta of 2.17. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The business had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.Kymera Therapeutics’s revenue for the quarter was down 55.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.58) EPS. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. UBS Group cut their target price on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Jefferies Financial Group set a $64.00 target price on Kymera Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 25th. The Goldman Sachs Group upgraded Kymera Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 15th. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They set a “buy” rating and a $55.00 price objective for the company. Finally, Oppenheimer reiterated an “outperform” rating and set a $53.00 price objective (down from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Kymera Therapeutics has a consensus rating of “Buy” and an average target price of $58.76.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bros. Advisors Lp Baker bought 655,500 shares of the firm’s stock in a transaction dated Monday, June 30th. The shares were bought at an average price of $44.00 per share, for a total transaction of $28,842,000.00. Following the completion of the acquisition, the director owned 6,117,295 shares of the company’s stock, valued at approximately $269,160,980. This trade represents a 12.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bvf Partners L. P/Il bought 317,167 shares of the firm’s stock in a transaction dated Monday, June 30th. The shares were acquired at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the acquisition, the director directly owned 2,798,795 shares of the company’s stock, valued at approximately $123,146,980. The trade was a 12.78% increase in their position. The disclosure for this purchase can be found here. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.